EYEN: יתרות מזומנים למניה eyenovia.com

Eyenovia, Inc. (EYEN) is developing ocular micro-dosing systems, leveraging its patent portfolio to ensure high margins following FDA approval. Cash per share for the period illustrates liquidity, where the 1.35 level represents the current value. The company's innovative micro-sprays replace traditional drops, guaranteeing uniform coverage of the eye surface. Meanwhile, device assembly is outsourced to external plants, keeping the formulas proprietary.
פילוחי מדדים מקיפים ואנליטיקה עבור Eyenovia (EYEN)

This indicator reflects the actual amount of free capital per share. The calculation is based on dividing cash from all liquid assets by the total number of shares. By analyzing the dynamics of the liquid position per share, an investor assesses the issuer's solvency without resorting to borrowed funds. For Eyenovia, Inc. (EYEN), this resource is critical for financing R&D projects. The compensation of highly qualified biomedical specialists and engineers correlates directly with the depletion of this liquid cushion.